A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs Crizotinib (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2021.
    • 09 Apr 2015 Protocol has been amended to change in treatment arms and endpoint.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top